Skip to main content
. 2015 Oct 15;5:15403. doi: 10.1038/srep15403

Figure 7. Lipogenic effect of p17 is neutralized with AT20 peptide or LXR antagonism.

Figure 7

(A–C) Serum starved HepG2 cells were pre-incubated 2 h with the serum taken from an HIV patient vaccinated with a recombinant p17 peptide, diluted 1:100 in culture medium, followed by additional treatment with 10 μg/ml p17 for 18 hours. qRT-PCR of LXRα (A), SREBP1c (B) and FAS (C). (D–F) Serum starved HepG2 cells were pre-incubated 2 h with 10 μM LXR antagonist gymnestrogenin, followed by additional treatment with 10 μg/ml p17 for 18 hours. qRT-PCR of LXRα (D), SREBP1c (E) and FAS (F). Values are normalized relative to GAPDH mRNA and are expressed relative to those of untreated cells, which were arbitrarily set to 1. *P < 0.05 versus not treated cells. #P < 0.05 versus p17 stimulated cells. Gymn: gymnestrogenin.